Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Bristol-Myers Squibb CompanyNYSE: BMY

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures dips below year-ago levels

Q2 FY2026 capital expenditures of $305M (cash outflow) fell 15.5% year over year, behind the +1.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Capital expenditures amounted to 2.7% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Capital expenditures grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.5% toward the trailing-twelve-month pace of +1.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$305M-12.1% QoQ
Last fiscal yearDec 2025
-$1.31B+5.0% YoY
LTMJun 2026
-$1.34B+1.4% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.5%——
1 year+5.0%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.31B) USD
Year-over-year change
-5.0%

Capital Expenditures vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.4% is the 5th highest of 11, against a peer median of -19.5%.
  • Capital expenditures amounts to 2.7% of revenue for BMY, versus a peer median of 5.5%.
BMY Competitors
Capital Expenditures for BMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$8.03B USD-26.9%+38.0%10.1%
JNJJohnson & JohnsonLTM Sep 2026$5.57B USD+8.6%+6.4%5.6%
AZNAstraZeneca PLCLTM Sep 2026$4.01B USD-28.0%+31.9%6.5%
MRKMerck & Co., Inc.LTM Jun 2026$3.9B USD+2.4%-2.1%5.9%
NVSNovartis AGLTM Jun 2026$2.57B USD-35.5%-11.4%4.6%
PFEPfizer Inc.LTM Jun 2026$2.42B USD-12.1%-6.7%3.8%
AMGNAmgen Inc.LTM Jun 2026$2.3B USD+63.6%+25.7%6.0%
GSKGSK plcLTM Jun 2026£1.76B GBP-42.4%-2.2%5.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$1.34B USD+1.4%+5.5%2.7%
ABBVAbbVie Inc.LTM Jun 2026$1.3B USD+24.2%+20.4%2.0%
GILDGilead Sciences, Inc.LTM Jun 2026$352M USD-29.5%-8.2%1.2%
Peer median (excluding BMY) —-19.5%+2.1%5.5%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.01B6.35B8.04B(8.93B)7.06B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
Deferred Income Tax(1.39B)(2.74B)(3.29B)(2.09B)(965M)
Stock-Based Compensation583M457M518M507M553M
Change in Working Capital(1.26B)(2.23B)(1.91B)810M(455M)
Accounts Receivables(1.05B)(663M)(995M)264M(295M)
Inventory13M(69M)(751M)(486M)(184M)
Accounts Payables245M109M198M184M(2M)
Other Working Capital(465M)(1.61B)(366M)848M26M
Other Non-Cash Items578M955M744M15.3B3.96B
Operating Cash Flow16.21B13.07B13.86B15.19B14.16B
Capital Expenditures(973M)(1.12B)(1.21B)(1.25B)(1.31B)
Acquisitions (Net)(862M)(2.98B)(260M)(20.72B)(2.87B)
Purchases of Investments(5.48B)(3.59B)(1.77B)(769M)(2B)
Sales of Investments6.78B6.63B948M1.39B2.05B
Other Investing Activities00000
Investing Cash Flow(538M)(1.06B)(2.3B)(21.35B)(4.13B)
Debt Repayment(6.18B)(5.31B)456M10.1B(5.18B)
Common Stock Issued000(106M)(128M)
Common Stock Repurchased(6.29B)(8B)(5.16B)00
Dividends Paid(4.4B)(4.63B)(4.74B)(4.86B)(5.05B)
Other Financing Activities641M984M27M00
Financing Cash Flow(16.22B)(16.96B)(9.42B)5.13B(10.35B)
Effect of Forex Changes(102M)(33M)45M(137M)187M
Net Change in Cash(657M)(4.99B)2.19B(1.17B)(137M)
Free Cash Flow15.23B11.95B12.65B13.94B12.85B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.